1. Greece Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Lavipharm S.A.

Lavipharm S.A.

LAVI.AT
Lavipharm S.A.GR flagAthens Stock Exchange
1.53
EUR
+0.01
- -
261.97MMarket Cap
Lavipharm S.A.
LAVI.AT
(Athens Stock Exchange)

Recent

price

1.53

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
1.74
1.86
1.84
2.06
2.33
1.81
0.28
- -
0.37
Revenue per Share
0.71
0.07
0.29
0.11
0.1
0.04
0.01
- -
0.04
Basic EPS, GAAP
0.04
0.02
0.03
0.08
0.13
-1.5
-0.02
- -
0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
0.02
Dividend per Share
-6.61
-6.6
-6.31
-6.16
-6.52
0.75
0.11
- -
0.17
Book Value per Share
-1.26
-1.21
-0.97
-0.83
-0.77
-0.27
-0.01
- -
0.04
Tangible Book Value per Share
18
18
18
18
17
22
168
- -
168
Basic Weighted Avg Shares
32
34
34
38
40
39
48
53
63
Sales/Revenue/Turnover
9.26
14.42
13.54
13.57
13.55
9.56
9.6
10.34
14.39
Operating Margin (%)
2
1
1
2
2
2
4
5
5
Depreciation Expense
13
1
5
2
2
1
2
9
6
Net Income, GAAP
- -
56.27
- -
36.6
37.1
57.95
38.77
- -
32.69
Effective Tax Rate (%)
40.64
3.67
15.86
5.56
4.34
2.14
3.91
16.96
9.56
Profit Margin (%)
- -
4
4
5
-15
- -
10
6
9
Working Capital
40
38
38
35
15
15
24
22
21
LT Debt
-20
-20
-14
-12
-10
40
43
53
56
Total Equity
- -
8.43
- -
11.72
11.98
2.93
3.63
- -
6.83
Return on Invested Capital (%)
- -
-2.61
- -
-4.45
-3.89
-14.86
6.19
- -
11.81
Return on Capital (%)
- -
- -
- -
- -
- -
- -
11.05
40.34
21.45
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-96.78%
6.51%
Free Cash Flow
- -
-341.8%
-140.91%
Net Income, GAAP
- -
80.34%
-33.36%
Sales/Revenue/Turnover
- -
11.04%
18.2%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
48
2024
- -
- -
- -
- -
53
2025
- -
- -
- -
- -
63

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.02
Similar Companies
Journey Medical Corporation (DERM)
Syncom Formulations (India) Limited (SYNCOMF.NS)
Aurora Cannabis Inc. R (21P.F)
Aarey Drugs & Pharmaceuticals (AAREYDRUGS.BO)
MGC Pharmaceuticals Limited (MGCLF)
Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)
Business
Lavipharm S.A. is a pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of pharmaceutical products and healthcare solutions. Its core product portfolio includes prescription medicines, over-the-counter (OTC) pharmaceuticals, branded generics, and consumer health products. The company offers a diverse range of pharmaceutical formulations such as tablets, capsules, injectable solutions, syrups, and topical products. Lavipharm operates mainly in Greece and the broader Southeastern European region, focusing on serving healthcare providers, pharmacies, and end consumers. Founded in 1911, the company is headquartered in Athens, Greece. In recent years, Lavipharm has undertaken strategic initiatives to expand its product offerings and strengthen its market presence. While explicit detailed major changes for 2024-2025 were not publicly highlighted, Lavipharm is known to consistently evolve through new product launches in the pharmaceutical and healthcare segments and has shown ongoing commitment to partnerships and collaborations within the industry to support growth and innovation. Its focus remains on enhancing its portfolio with effective medicines and consumer health products to meet regional healthcare demands and regulatory standards. Lavipharm's operations span research and development, manufacturing, and distribution, aligning with its mission to provide quality healthcare solutions. It serves various therapeutic areas including cardiovascular, central nervous system, antibiotics, and dermatology. The company also manages subsidiary relationships and adapts to regulatory environments within its geographic footprint to maintain compliance and competitiveness. As a long-established firm, Lavipharm continuously invests in innovation and development to adapt to evolving healthcare needs in its target markets.